Residential Treatment
'REHAB'
Last Week Tonight with John Oliver
(“Rehab is a $35 billion industry with no federal standards, and the vast majority of people in need of addiction treatment do not receive anything that approximates evidence-based care. . .”) May 2018.
TREATMENT & REGULATION
IN MOST RESIDENTIAL PROGRAMS
IS INEFFECTIVE
FOR OPIOID USE DISORDER
Short-term, residential care (“Rehab”) accounts for over a quarter of national spending on substance use treatment, and many policymakers promote increasing the number of “treatment beds.” However, “residential treatment programs may . . . result in a higher risk of overdose and mortality than outpatient treatment due to a focus on ‘detoxification’ rather than evidence-based Opioid Agonist Treatments (OAT, aka methadone or buprenorphine).” (Beetham, et al. 2021, below).
For information on higher overdose and mortality in residential treatment, see:
Beetham et al. Admission Practices and Cost of Care for Opioid Use Disorder at Residential Addiction Treatment Programs in the U.S. Health Affairs (Millwood). 2021 Feb;40(2):317–325.
Strang J, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 2003;326(7396):959–60.
Heimer R, et. al. Receipt of opioid use disorder treatments prior to fatal overdoses and comparison to no treatment in Connecticut, 2016–17. Drug and Alcohol Dependence. Volume 254, January 2024, 111040.
Wines JD, et al. Overdose after detoxification: A prospective study. Drug Alcohol Depend 2007;89(2–3):161–9.
FEDERAL LAWS PROTECTING
MOUD ACCESS: NECESSARY BUT
NOT SUFFICIENT
Ironically, the existence of some laws and accreditation standards may leave the impression that the industry is appropriately regulated. The existence of the federal Americans with Disabilities Act (ADA) has been used to try to persuade lawmakers & regulators that state regulations prohibiting limits on the use of MOUD in licensed facilities – are unnecessary, because this is already illegal on the federal level (in some circumstances). According to this argument, victims of discrimination over MOUD access need only report this to the relevant federal agency. This amounts to relying on nearly non-existent enforcement since few victims are able to hire lawyers for multi-year legal battles, if they are even aware of these laws. In the case of recovery residences, federal laws have *never* been used to protect MOUD access, with the possible exception of a single lawsuit, Tassinari v. The Salvation Army filed in May of 2021 and still ongoing as of July 2026. There have been important victories resulting from legal action to enforce these federal laws but these are the ‘exceptions that prove the rule,’ since ongoing illegal discrimination remains rampant both in residential treatment and recovery housing.
Ongoing feedback, support, and access to information promotes adoption of evidence-based practices across other organizational settings (Wood, et al. 2022). Since accurate counseling and understanding is critical in forming preferences about using MOUD, it seems that a client handout with un-biased information on MOUD could be required and approved by regulators
Wood CA, et al. Acceptance of medications for opioid use disorder in recovery housing programs in Missouri.J Subst Abuse Treat. 2022 Jul;138:108747. READ ABSTRACT
ACCREDITATION: THE MISLEADING
‘SEAL OF APPROVAL:
Similarly, the nearly ubiquitous requirement that licensed residential treatment facilities be accredited by a private accreditation body may give the impression that all is well. Approximately half of the states require this for state licensure, and it is also required by Medicaid, most private insurers and for SAMHSA grantees.
It may be reassuring that one of the accreditation standards by The Joint Commission (TJC) is “Evidence‑based treatment approaches including access to medication for OUD …” Yet, most accredited facilities do not allow the use of maintenance MOUD. The failure of accreditation is related to the fact that the big two accreditation bodies each have over a thousand standards or components of standards, updated annually or twice a year. It is probably impossible for providers to be aware of, let alone comply with this volume. The health policy literature has also critiqued the practice of outsourcing regulation to private entities that operate as paid vendors that compete for market share, hired by the entities they oversee. There is a well-known focus on written policies over actual practices. If a deficiency is recognized, the remedy is typically a requirement to update policies to show how the program intends to fix the problem in the future, a paperwork exercise.
In a secret shopper study of a national sample of 368 residential treatment programs, over a third of accredited programs used clearly inappropriate admission procedures over-the-phone without an evaluation, while over half used inappropriate recruitment techniques, both at higher rates than non-accredited programs. (Beetham T, et al. 2021, below)
In a secret shopper study of a national sample of 368 residential treatment programs, over a third of accredited programs used clearly inappropriate admission procedures over-the-phone without an evaluation, while over half used inappropriate recruitment techniques, both at higher rates than non-accredited programs. (Beetham T, et al. 2021, below)
In a secret shopper study of a national sample of 368 residential treatment programs, over a third of accredited programs used clearly inappropriate admission procedures over-the-phone without an evaluation, while over half used inappropriate recruitment techniques, both at higher rates than non-accredited programs. (Beetham T, et al. 2021, below)
The wide variation between states in MOUD access is striking. The percentage of *accredited* addiction treatment facilities providing medications for opioid use disorder ranged from 15 percent (Colorado, N. Dakota) to 89 percent (Alaska, Wyoming). Half or fewer offered MOUD (Tami L, 2020, below). This is one factor that points to state regulations of licensed facilities as being perhaps the most likely path to enforcement of MOUD access, along with education and support of providers. However, not all state regulations are effective, as described by Beetham T., et al. 2021, below).
Wood CA, et al. Acceptance of medications for opioid use disorder in recovery housing programs in Missouri. J Subst Abuse Treat. 2022 Jul;138:108747. doi: 10.1016/j.jsat.2022.108747. Epub 2022 Feb 20. PMID: 35248406
Tami L, et al. Tracking the Quality of Addiction Treatment Over Time and Across States: Using the Federal Government’s “Signs” of Higher Quality Research Triangle Park (NC): RTI Press; 2020 Jul.
Beetham T et al. Admission Practices and Cost of Care for Opioid Use Disorder at Residential Addiction Treatment Programs in the U.S. Health Affairs (Millwood). 2021 Feb;40(2):317–325.
However, facilities that allow MOUD can be very effective, and are a critical part of the treatment and recovery continuum.
de Andrade D, et al. (2019). The effectiveness of residential treatment services for individuals with substance use disorders: A systematic review. Drug and Alcohol Dependence, 201, 227–235.
Stahler GJ, et al. (2020). The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US. Drug and Alcohol Dependence, 212, 108067.
MOST RESIDENTIAL TREATMENT FACILITIES DO NOT ALLOW ACCESS TO MAINTENANCE MEDICATIONS
FOR OUD (ANNOTATED BIBLIOGRAPHY)
TWO THIRDS OF RESIDENTIAL PROGRAMS DID NOT OFFER MAINTENANCE OPIOID AGONIST THERAPY
(This is a 2020 publication by the same authors, and with the same data collection methods, as Beetham T, et al. 2021, above).
In a random sample of U.S. residential treatment programs, an equal proportion of for-profit and nonprofit (including public) programs were randomly selected. 368 of 453 programs were contacted (81% response rate). 29% offered opioid agonist therapy (OAT) with the option to continue maintenance. An additional 31% offered OAT only for short-term detoxification, while 39% did not offer OAT or were unclear about whether OAT was available. 21% actively discouraged callers from using OAT. (This indicates that the treatment of OUD in most such facilities is ineffective).
Beetham T, Saloner B, Gaye M, Wakeman SE, Frank RG, Barnett ML. Therapies Offered at Residential Addiction Treatment Programs in the United States. Research Letter, August 25, 2020. JAMA. 2020; 324(8):804-806
ANOTHER MYSTERY SHOPPER STUDY:
THREE QUARTERS DID NOT OFFER MOUD
Among 160 adolescent residential addiction treatment facilities contacted in a mystery shopper survey using a scenario of a 16-year-old with a recent nonfatal fentanyl overdose seeking treatment for OUD . . .
10.6% offered buprenorphine initiation with ongoing treatment;
7.5% offered buprenorphine initiation but with discontinuation before discharge
(A total of 24.4% offered buprenorphine in some manner)
King C, et al. Treatments Used Among Adolescent Residential Addiction Treatment Facilities in the US, 2022. JAMA. 2023;329(22):1983–1985.
VERY LOW RATES OF EFFECTIVE OUD TREATMENT (FOR MOUD) IN RESIDENTIAL TREATMENT
In cross-sectional data from 2,863 residential treatment facilities, few offered extended-release naltrexone (29.8%), buprenorphine (33.3%), or methadone (2.1%). Regarding residential treatment admissions (n=232,414), MOUD was utilized in only 17.3% and 1.9% of admissions in states that did or did not expand Medicaid, respectively. 60% of facilities offered no medications for OUD. (1% offered all 3 FDA approved types of MOUD).
Huhn AS, et al. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States. JAMA Netw Open. 2020;3(2):e1920843.
ONE IN FIVE HAD MOUD IN THEIR TREATMENT PLANS
IN SHORT- AND LONG- TERM TREATMENT
Assessed treatment completion and retention in a national dataset of Short-term (>10 days; n = 87,296) and Long-term (>90 days; n = 66,623) residential treatment, controlling for background characteristics. MOUD treatment was associated with a higher rate of treatment retention. Only 18% of clients in residential treatment programs had MOUD in their treatment plans. The authors concluded that MOUD is particularly under-utilized in residential treatment.
Stahler GJ, & Mennis J. The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US. Drug Alcohol Depend. 2020 Jul 1:212:108067.
LACK OF FOLLOW-UP, OR MOUD, AFTER DISCHARGE
FROM RESIDENTIAL TREATMENT
Follow-up after residential treatment is considered best practice for OUD. Medicaid claims data were used to identify any follow-up outpatient visits at 30 days after discharge among Medicaid enrollees in 10 states in 90,639 episodes of residential treatment for OUD from 2018 to 2019.
47% of episodes did not receive any follow-up or MOUD at 30 days post-discharge. The authors concluded that these episodes did not follow best practices.
Allen L, et al. Outpatient Follow-Up and Use of Medications for Opioid Use Disorder after Residential Treatment among Medicaid Enrollees in 10 States. Drug Alcohol Depend. 2022 Oct 21;241:109670.
MEDICAID REQUIREMENTS: A LEVER TO ESTABLISH
STATE REGULATIONS FOR MOUD ACCESS
Across the 50 states and DC, the temporal relationship between state regulations regarding MOUD in residential settings, and Section 1115(a) demonstrations, were examined. 11 states have established rights to MOUD as a requirement for SUD Residential Treatment Facilities. In 18 states, regulatory approaches included identifying opioid medication treatment as a right, requiring MOUD access, and similar requirements. 25 of 30 states with approved Section 1115(a) demonstrations included explicit requirements for MOUD access. State regulations and Medicaid program requirements are policy levers to facilitate OUD medication treatment access.
O’Brien PL, e al. (2022). Residential treatment and medication treatment for opioid use disorder: The role of state Medicaid innovations in advancing the field. Drug and Alcohol Dependence Reports, 4, 100087.
DESPITE POOR OUTCOMES, TREATMENT PROGRAMS
HAVE BEEN ADAMANTLY OPPOSED TO MOUD
“Mainstream addiction treatment programs, despite poor treatment outcomes for OUD, have historically been adamantly opposed to using medications for OUD beyond withdrawal management. . . The future of MOUD rests upon [among seven other recommended activities] assertively addressing personal, programmatic, and community obstacles to OUD treatment adherence and retention.” This monograph was authored by leaders in addiction medicine.
White, W. L., Galanter, M., Kolodner, G., Kepner, W. E., Sarapas, C. & Mouton, C. L. (2025). Medications for opioid use disorder: Enhancing retention to achieve long-term remission and recovery. Chestnut Health Systems, Lighthouse Institute.
Read a summary of this article in ‘Recovery Review,’ a community of recovery-oriented experts.
WE NEED TO GET REAL WITH ENFORCEMENT OF MOUD ACCESS
25 specific strategies to address barriers that limit access to effective medical treatment were identified, with a focus on addressing barriers limiting access to MOUD in health care settings. These include:
“Agencies or organizations responsible for the accreditation and licensing of substance use treatment facilities. . . should ensure that providing access to effective medications as a condition of accreditation and licensure for treatment of opioid use disorder,” and
“SAMHSA, NIDA, and CMS should … phase out funding for addiction treatment programs that do not offer evidence-based care, including medications to treat opioid use disorder.”
Madras BK, Ahmad NJ, Wen J, & Sharfstein JS (2020). Improving access to evidence-based medical treatment for opioid use disorder: Strategies to address key barriers within the treatment system. Review NAM Perspectives.
2020 Apr 27:2020
NO BENEFITS FOR THOSE WITH OUD IN RESIDENTIAL OR OUTPATIENT CARE
UNLESS MOUD IS INCLUDED.
A retrospective cohort study used linked data from a state Medicaid program, vital statistics, and the SAMHSA Treatment Episodes Dataset (TEDS) to compare OUD-related health outcomes among individuals treated in a residential or outpatient setting between 2014 and 2017. Independent of setting, MOUD use was associated with a significant reduction in overdose risk by about 50% (The adjusted hazard ratio, ‘aHR,’ was 0.45; 95% CI 0.23–0.89). Residential care was only associated with greater odds of retention for individuals not receiving MOUD. There were no benefits from residential care in those not taking MOUD.
The authors conclude that “We should expand outpatient MOUD treatment, not residential care.”
Hartung DM, et al. Association between treatment setting and outcomes among Oregon Medicaid patients with opioid use disorder: A retrospective cohort study. Addiction Science & Clinical Practice Aug, 2022; 17:45.
Read a summary of this article: ‘Residential vs. Outpatient Treatment for OUD: Which One Works Best?’ by the Addiction Technology Transfer Centers (ATTC): “Efforts to expand access to treatment should focus on building capacity for outpatient MOUD treatment, rather than on residential care.